Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 3/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118797 | 0.87 | NPSR1 (0.36) | NPSR1LMNAEIF4A3C5AR1KDM1A | |
| SCHEMBL10119927 | 0.84 | NPSR1 (0.34) | NPSR1EIF4A3 | |
| SCHEMBL15889025 | 0.83 | RAB9A (0.36) | PDE2A | |
| SCHEMBL12327996 | 0.83 | LMNA (0.39) | NPSR1LMNAPSMB5PDE2A | |
| SCHEMBL13561573 | 0.82 | TYMS (0.39) | NPSR1LMNAPSMB5PDE2A | |
| SCHEMBL10141013 | 0.76 | SLC6A2 (0.35) | — | |
| SCHEMBL12328338 | 0.72 | LMNA (0.36) | LMNAPSMB5PDE2A | |
| SCHEMBL12328339 | 0.71 | HPGD (0.37) | LMNAPSMB5PDE2A | |
| SCHEMBL12294482 | 0.70 | KDM4E (0.36) | NPSR1LMNAEIF4A3PSMB5 | |
| SCHEMBL15705289 | 0.69 | NPSR1 (0.42) | NPSR1LMNAKDM1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | NPSR1 2789/4885LMNA 2800/4885EIF4A3 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.